Tamoxifen and risk of contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. - Wikidata - awgldk - TriplyDB

Tamoxifen and risk of contralateral breast cancer for BRCA1 and BRCA2 mutation carriers.

Tamoxifen and risk of contralateral breast cancer for BRCA1 and BRCA2 mutation carriers.

http://www.wikidata.org/entity/Q37122297

about

BRCA1, a 'complex' protein involved in the maintenance of genomic stability Preventive treatments for breast cancer: recent developments Tailoring therapies--improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015 The validation and clinical implementation of BRCAplus: a comprehensive high-risk breast cancer diagnostic assay.Malignant Brenner tumor associated with a germline BRCA2 mutation.Modifiers of cancer risk in BRCA1 and BRCA2 mutation carriers: systematic review and meta-analysis.Estrogen Receptor-β and the Insulin-Like Growth Factor Axis as Potential Therapeutic Targets for Triple-Negative Breast Cancer.The PARP inhibitors, veliparib and olaparib, are effective chemopreventive agents for delaying mammary tumor development in BRCA1-deficient mice Duration of tamoxifen use and the risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers Synchronous uterine carcinosarcoma and contralateral breast cancer after tamoxifen therapy: a case report Prognostic factors of second primary contralateral breast cancer in early-stage breast cancer.Risk of contralateral second primary breast cancer according to hormone receptor status in Germany.Therapeutic targeting of BRCA1-mutated breast cancers with agents that activate DNA repair Biologic roles of estrogen receptor-β and insulin-like growth factor-2 in triple-negative breast cancer.Repeated nipple fluid aspiration: compliance and feasibility results from a prospective multicenter study Genetics of breast cancer: a topic in evolution.Second primary breast cancer in BRCA1 and BRCA2 mutation carriers: 10-year cumulative incidence in the Breast Cancer Family Registry.DCIS in BRCA1 and BRCA2 mutation carriers: prevalence, phenotype, and expression of oncodrivers C-MET and HER3.Adjuvant radiotherapy for primary breast cancer in BRCA1 and BRCA2 mutation carriers and risk of contralateral breast cancer with special attention to patients irradiated at younger age.SEOM clinical guidelines in Hereditary Breast and ovarian cancer.Comparative genomic analysis reveals bilateral breast cancers are genetically independent Transforming Cancer Prevention through Precision Medicine and Immune-oncology.Genomic Biomarkers for Breast Cancer Risk.Proliferation and ovarian hormone signaling are impaired in normal breast tissues from women with BRCA1 mutations: benefit of a progesterone receptor modulator treatment as a breast cancer preventive strategy in women with inherited BRCA1 mutations.Tamoxifen for women at high risk of breast cancer.Counterpoint: Angelina's choice-or the choice of anyone else in her place.Lower mitotic activity in BRCA1/2-associated primary breast cancers occurring after risk-reducing salpingo-oophorectomy.Bilateral breast cancers.Genetic testing today.BRCA1 and BRCA2 mutations and the risk for colorectal cancer.Preferences for breast cancer risk reduction among BRCA1/BRCA2 mutation carriers: a discrete-choice experiment.Surgical Decision Making in the BRCA-Positive Population: Institutional Experience and Comparison with Recent Literature.The selective estrogen receptor modulators in breast cancer prevention.Endocrine therapy for breast cancer prevention in high-risk women: clinical and economic considerations.Cost-effectiveness of different strategies to prevent breast and ovarian cancer in German women with a BRCA 1 or 2 mutation.Time to incorporate germline multigene panel testing into breast and ovarian cancer patient care.Can we prevent BRCA1-associated breast cancer by RANKL inhibition?Breast Cancer Survival of BRCA1/BRCA2 Mutation Carriers in a Hospital-Based Cohort of Young Women.Bilateral Oophorectomy and Breast Cancer Risk in BRCA1 and BRCA2 Mutation Carriers.Risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a 30-year semi-prospective analysis.

P2860

Q26853262-F58EBDCE-FD67-48D3-8777-0BE33FE3FF5A Q27025375-AE22E2B6-E421-4B9B-A798-CB9B5268C365 Q28085062-B51FC3DF-81C7-4049-9B99-980814889A4A Q33618536-9AE240FC-7599-404A-8868-C901D4034A57 Q33763270-95F25AA6-8B82-44E9-9034-4B087A59AC8E Q33845209-D43918B0-3A88-4DA1-BF29-C02AA49B3BE4 Q33866151-BE7696D1-6345-49C7-8E1B-7872C162053F Q33874466-D14CC170-480F-4173-A1FF-55B7D0748CB8 Q34039438-12EE0096-ADA6-4EBE-86A0-71F08434C3D9 Q34121698-87FC010C-0852-4CDF-8B8D-C82E9D0360C0 Q34582515-62A8C718-5E42-43A3-BC9B-1EAA685D9A33 Q35000330-AD040E46-9BA1-48A6-B17C-5F1774DE6429 Q35251010-3197FD86-D768-485A-9846-B7AD80AB733C Q35271188-4C5F439C-8A22-4C03-93FF-E23DD1052B1F Q35637243-3AA35D34-F490-4C96-8FC1-8DB2462463CC Q35775223-329C5F31-CBC8-4274-B492-ABDF3086F85F Q35983751-249E4548-02C0-4BE2-94D5-9A8E361DFC0B Q36203244-11E2684A-C6DA-4EE5-A176-16F032950FBF Q36210166-F73B2977-7F84-47F4-8B06-1D6A099A80C0 Q36400244-6A62AD4E-75AC-4487-BE29-0D697AB0932D Q36544696-F87C45F4-6108-4330-8807-ED8DA663F0E3 Q37114360-81901CE6-C4B6-4121-A0B5-477640A02995 Q37242239-3EF851D2-66E3-4D59-A326-A651F6B6CC1F Q37564411-CCBD114B-AF95-465E-859A-79273A0ECD22 Q37600675-76FD50E0-8C9C-41D9-AEE5-89D9844CD4E6 Q37654018-B1E60B1C-3E93-4EDD-AEF9-60F1EEC4EA16 Q37692442-F24F73E6-D5C0-43B1-86D6-E2FAC305024F Q38184906-90FCFBDE-8229-4A14-9778-E74B411A61E4 Q38230196-B26B31C3-1696-4BAB-A08D-834F359898F7 Q38246631-E0AB24B5-96A9-440E-9D1A-3E8559C10C98 Q38669803-F3A64E3A-BF3E-4A8E-A9DE-98A91C89B37E Q38676694-6580578D-F23F-43A6-A1C1-C9ED21C46270 Q38703578-32EDD269-CAF9-44B7-802B-C894322397CC Q38753738-26BC31B0-6E0E-4EB0-AAB8-435DB824731F Q38851169-A003CF50-24C1-4AC5-BD16-06E39DA5AD9C Q38979257-EA9F8618-6864-4B95-B800-B92BDCEFA071 Q38991293-C0F87BE0-1B84-4290-BF3B-AB8DF9FF84E4 Q40258706-AAF555A6-3B81-44B1-A1B8-8DDF459CEF8F Q40592257-5128D8E2-B74C-4033-A86A-0C568E52F102 Q41517367-4FF01CC1-86A2-4F60-B717-AF5D8581A07B

P2860

Tamoxifen and risk of contralateral breast cancer for BRCA1 and BRCA2 mutation carriers.

http://www.wikidata.org/entity/Q37122297

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 05 August 2013

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Tamoxifen and risk of contralateral breast cancer for BRCA1 and BRCA2 mutation carriers.

@en

Tamoxifen and risk of contralateral breast cancer for BRCA1 and BRCA2 mutation carriers.

@nl

type

label

Tamoxifen and risk of contralateral breast cancer for BRCA1 and BRCA2 mutation carriers.

@en

Tamoxifen and risk of contralateral breast cancer for BRCA1 and BRCA2 mutation carriers.

@nl

prefLabel

Tamoxifen and risk of contralateral breast cancer for BRCA1 and BRCA2 mutation carriers.

@en

Tamoxifen and risk of contralateral breast cancer for BRCA1 and BRCA2 mutation carriers.

@nl

P1433

Q37122297-8A301946-B4FE-4D93-8534-BB62A245FDDE

P1476

Q37122297-63953EB3-36BD-4794-8C62-DB9D3B4478A2

P2093

Q37122297-00C2C0B3-4E65-4790-B226-D8F2163A7F70

Q37122297-1D87C5AB-8FAA-4A3F-8940-3DCFB4A302C9

Q37122297-36540BF6-947A-4B5E-87B6-6742CABE1FA7

Q37122297-3F3CAAB4-B315-456F-867B-931F1DBD0B28

Q37122297-409FA59D-2A6E-49AF-B85A-51D954B47D46

Q37122297-4BD9763B-2A00-41BE-84E7-06685B9C5B42

Q37122297-808541A4-E58A-46D6-8CC3-03BF444BE7FF

Q37122297-836EE2CB-48D9-4567-8881-7AAC8AB303FB

Q37122297-8F441D0A-040B-4FB2-84A6-443560F98BE4

Q37122297-987B9EBF-E57F-436F-9502-5B8D287C7E1D

P2860

Q37122297-0246EF18-5A14-4C4B-A1DD-1FD5F82F3BA2

Q37122297-049AC8B2-C5A8-4CC1-8335-D60F9CB73536

Q37122297-066B7223-D229-43C5-A4E8-E4D426A5DA6D

Q37122297-08A2D560-CB86-4CA5-B2C3-09E5038B1C9A

Q37122297-09373A7D-3179-4EF0-887A-3622AB1A140C

Q37122297-145EA754-676E-4C7F-9309-C052E8C53848

Q37122297-14924CBA-D6C4-48AE-8ACE-B6D15A9FA25E

Q37122297-24C808B3-B946-4607-B2EC-3E1F9FB6EED7

Q37122297-2DFF1081-1781-41FA-8D25-A05A9DF8DD50

Q37122297-33519A03-4450-49BC-A4CE-BE1CF2262063

P304

Q37122297-635C2391-CBCC-49B6-8961-61C245659A4B

P31

Q37122297-315337E1-6269-4786-A126-FA1887E0A1AB

P356

Q37122297-378394F0-45DD-4AC2-8F1B-CA450E2290D6

P407

Q37122297-CF927923-E11A-4376-8C3F-331EF0042C73

P433

Q37122297-C5B476F2-8C6F-4730-A5D3-4525B02E3FC9

P478

Q37122297-70F1F523-E117-4173-9270-AC7E8673A9F6

P50

Q37122297-0054EF31-9FE8-479C-A7DF-881FDB80880B

Q37122297-0443CD88-F365-401D-9501-5B07557995C3

Q37122297-0FBA938B-2386-4CF7-B76D-7AD9CC6E886A

Q37122297-21DF2FAF-F412-4637-8306-37324371E547

Q37122297-343037A9-F227-441A-8CE3-F02F183053BB

Q37122297-37F1B74A-067E-46F5-8882-28B40CBFD686

Q37122297-422BC5B3-B6F5-44CD-AFAC-ED9586470A21

Q37122297-49DFEFBF-6DCF-4677-B035-A27B0F5D8553

Q37122297-4E7CB6FD-CBED-4BE2-9E1F-37F0483A342F

Q37122297-52F92899-221A-4C02-8514-4B36025E39CC

P577

Q37122297-E705DF9F-4E4F-4CE8-B319-7CCC70015DCC

P698

Q37122297-C871C247-AD6E-46CA-BD4B-74A48C6538CB

P932

Q37122297-4952BA64-4CD8-4B3E-9F49-CE64272A0ED8

P356

JCO.2012.47.8313

P1433

Journal of Clinical Oncology

P1476

Tamoxifen and risk of contralateral breast cancer for BRCA1 and BRCA2 mutation carriers.

@en

P2093

Catherine Noguès

http://www.w3.org/2001/XMLSchema#string

Christian F Singer

http://www.w3.org/2001/XMLSchema#string

David E Goldgar

http://www.w3.org/2001/XMLSchema#string

Edith Olah

http://www.w3.org/2001/XMLSchema#string

Kate Birch

http://www.w3.org/2001/XMLSchema#string

Mary B Daly

http://www.w3.org/2001/XMLSchema#string

Matti A Rookus

http://www.w3.org/2001/XMLSchema#string

Michael L Friedlander

http://www.w3.org/2001/XMLSchema#string

Nadine Andrieu

http://www.w3.org/2001/XMLSchema#string

Pascal Pujol

http://www.w3.org/2001/XMLSchema#string

P2860

Prophylactic mastectomy for the prevention of breast cancer

Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies

The Breast Cancer Family Registry: an infrastructure for cooperative multinational, interdisciplinary and translational studies of the genetic epidemiology of breast cancer

Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study

Long-term results of tamoxifen prophylaxis for breast cancer--96-month follow-up of the randomized IBIS-I trial

Tamoxifen for the prevention of breast cancer: late results of the Italian Randomized Tamoxifen Prevention Trial among women with hysterectomy

Adjuvant systemic therapy for breast cancer in BRCA1/BRCA2 mutation carriers in a population-based study of risk of contralateral breast cancer

Population-based study of the risk of second primary contralateral breast cancer associated with carrying a mutation in BRCA1 or BRCA2.

Expression of estrogen receptor beta in the breast carcinoma of BRCA1 mutation carriers

Epidemiology of contralateral breast cancer.

P304

3091-3099

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2012.47.8313

http://www.w3.org/2001/XMLSchema#string

P407

P433

25

http://www.w3.org/2001/XMLSchema#string

P478

31

http://www.w3.org/2001/XMLSchema#string

P50

Dominique Stoppa-Lyonnet

Lenka Foretová

Caroline Seynaeve

Kelly-Anne Phillips

Anne-Marie Gerdes

Melissa C. Southey

Prue C Weideman

Anna Jakubowska

P577

2013-08-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23918944

http://www.w3.org/2001/XMLSchema#string

P932

3753701

http://www.w3.org/2001/XMLSchema#string